Vutrisiran Cuts Risk of Advanced ATTR-CM, Improves Outcomes in Those Who Progress

New analyses from the phase 3 HELIOS-B trial (NCT04153149) offer a more in-depth picture of vutrisiran's (Amvuttra; Alnylam) impact in transthyretin amyloid cardiomyopathy (ATTR-CM), showing the RNA interference therapeutic reduced the likelihood of patients reaching advanced stages of heart failure (HF) and, for those who did progress, meaningfully improved clinical outcomes.1

The findings, presented at the American College of Cardiology 2026 Annual Scientific Session, examined patients from both the overall HELIOS-B population and a monotherapy subgroup. The aim of the study was to evaluate whether vutrisiran prevented progression to advanced disease and if it improved outcomes in patients who ultimately reached that advanced threshold.